<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461199</url>
  </required_header>
  <id_info>
    <org_study_id>02KOHAM</org_study_id>
    <nct_id>NCT02461199</nct_id>
  </id_info>
  <brief_title>Stool Transplantation to Reduce Antibiotic Resistance Transmission</brief_title>
  <acronym>START</acronym>
  <official_title>Prospective Observational Study of Fecal Microbiota Transplantation Used to Eradicate Gut-colonizing Multidrug-resistant Bacteria in Patients With Blood Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During this prospective observational study, the investigators collect the information about
      the outcomes of fecal microbiota transplantation in patients with blood disorders, performed
      to eradicate gut colonization with multidrug-resistant (MDR) bacteria.

      Patients with blood disorders are characterized by poor diversity of gut microbiome, affected
      by repeated chemotherapy and antimicrobial treatments. This makes them vulnerable to
      colonization by pathogenic bacteria carrying genes responsible for antibiotic resistance. In
      case of gut mucosa injury and severe immune suppression, these colonizing bacteria may cause
      severe systemic infections. As the bacteria are secreted with the stool, the colonized
      patients become an epidemiologic threat to the others.

      Fecal microbiota transplantation (FMT) was shown to be very efficient in treatment of
      relapsed and refractory Clostridium difficile infection and became a standard treatment. In
      home institution, the investigators use FMT not only in case of Clostridium difficile
      colitis, but also in case of gut colonization with multidrug-resistant (MDR) bacteria. This
      is based on assumption that physiological gut flora may outcompete the pathogenic bacteria
      similarly as in case of Clostridium difficile and lead to loss of colonization. The procedure
      is performed in all patients colonized, who qualify according to listed inclusion and
      exclusion criteria .
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of gut colonizing bacteria as proven by at least two negative stool cultures.</measure>
    <time_frame>2 weeks to 6 months after fecal microbiota transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of gut colonizing bacteria as proven by PCR.</measure>
    <time_frame>2 weeks to 6 months after fecal microbiota transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infective episodes</measure>
    <time_frame>from day &quot;0&quot; (day of FMT) to 6 months after fecal microbiota transplantation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Blood Disorders</condition>
  <arm_group>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <description>Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbiota transplantation</intervention_name>
    <description>Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube</description>
    <arm_group_label>Fecal microbiota transplantation</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples collected before and after the procedure.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with blood disorders treated in the Department of Hematology, Oncology and
        Internal Diseases, with positive gut colonization status with MDR bacteria, who consent for
        fecal microbiota transplantation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 y

          -  Carrier status of MDR bacteria in stool: Klebsiella pneumoniae resistant to
             carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis
             VRE, Enterococcus faecium VRE, Enterobacter cloacae KPC+ or other MDR species
             documented by at least two stool cultures

          -  Blood neutrophil count &gt; 500/uL on the day of fecal microbiota transplantation

        Exclusion Criteria:

          -  Inability to obtain informed consent and lack of consent

          -  Blood neutrophil count &lt;500/uL on the day of fecal microbiota transplantation or
             expected decrease to the mentioned number within 2 consecutive days

          -  Intensive, myelosuppressive chemotherapy (e.g. DHAP, ICE, ESHAP, HD-Cy, HD-Ara-C, DA,
             conditioning before allogeneic stem cell transplantation, BEACOPP) planned within 2
             consecutive days

          -  Patients up to 1 month after hematopoietic stem cell transplantation

          -  Clinical signs of mucositis

          -  Severe liver failure

          -  Patients undergoing intensive antimicrobial treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grzegorz Basak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Oncology and Internal Diseases, the Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wieslaw Wiktor-Jedrzejczak, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, Oncology and Internal Diseases, the Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaroslaw Bilinski, MD</last_name>
    <phone>+48 22 599 29 44</phone>
    <email>jaroslaw.bilinski@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grzegorz W Basak, MD, PhD</last_name>
    <phone>+48 22 599 26 40</phone>
    <email>grzegorz.basak@wum.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Oncology and Internal Diseaes, The Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslaw Bilinski, MD</last_name>
      <phone>+48 22 599 29 44</phone>
      <email>jaroslaw.bilinski@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Grzegorz W Basak, MD, PhD</last_name>
      <phone>+48 22 599 26 40</phone>
      <email>grzegorz.basak@wum.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Grzegorz W Basak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaroslaw Bilinski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Grzegorz W. Basak</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>Gut colonization</keyword>
  <keyword>Multidrug-resistant bacteria</keyword>
  <keyword>Blood disorders</keyword>
  <keyword>Drug Resistance, Multiple</keyword>
  <keyword>Disease Eradication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

